BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31686124)

  • 1. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
    Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
    Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
    Tykodi SS; Satoh S; Deming JD; Chou J; Harrop R; Warren EH
    J Immunother; 2012 Sep; 35(7):523-33. PubMed ID: 22892449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
    Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
    Wang QJ; Hanada K; Feldman SA; Zhao Y; Inozume T; Yang JC
    J Immunol Methods; 2011 Mar; 366(1-2):43-51. PubMed ID: 21255579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.
    Bovay A; Zoete V; Dolton G; Bulek AM; Cole DK; Rizkallah PJ; Fuller A; Beck K; Michielin O; Speiser DE; Sewell AK; Fuertes Marraco SA
    Eur J Immunol; 2018 Feb; 48(2):258-272. PubMed ID: 28975614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.
    Redchenko I; Harrop R; Ryan MG; Hawkins RE; Carroll MW
    Immunology; 2006 May; 118(1):50-7. PubMed ID: 16630022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human leucocyte antigen class I-redirected anti-tumour CD4
    Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
    Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
    Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
    J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
    Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
    J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
    Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
    J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.